INTRODUCTION
Radical cystectomy, with a pelvic lymph-node dissection, is widely regarded as the 'reference standard' treatment for invasive bladder cancer [1] . Survival after cystectomy is predicted by the pathological stage of the primary bladder tumour and nodes, as well as the quality of cystectomy [2] . Chemotherapy may improve the subsequent survival [3] , but even with combined therapy the quality of surgery influences the outcome. For example, a subset analysis of a randomized, cooperative group trial of neoadjuvant chemotherapy plus cystectomy showed that the surgical factors of margin status, extent of node dissection, number of nodes resected and individual surgeon's experience (by training and volume) were independent predictors of overall survival [4] . Neoadjuvant chemotherapy was more likely to improve the survival of patients with muscle-invasive bladder cancer if they received a high-quality operation by an experienced surgeon. Despite mounting evidence that the quality of surgery matters, there are no universally accepted standards for radical cystectomy and pelvic node dissection, because the quality of surgery varies widely among individual surgeons and patients What constitutes an adequate radical cystectomy and pelvic node dissection for bladder cancer? What benchmarks can be used to define the quality of surgery in an individual patient? We attempted to derive a set of standards for radical cystectomy and node dissection by compiling the inclusive cystectomy experience of 16 surgeons operating on 1091 cases over 3 years (2000) (2001) (2002) from four centres experienced in treating bladder cancer [5] . Participating surgeons performed cystectomy for cure or palliation in 'all comers', regardless of age or comorbidity, and declined to operate in < 1% of patients for health reasons. Our collaborative surgical results reflect, as much as possible, what cystectomy can achieve in unselected patients presenting with diverse clinical situations.
We evaluated surgical and pathological features defined by radical cystectomy and pelvic node dissection among patients of varying ages, health states, clinical stages of bladder cancer, and previous treatments (pelvic surgery, chemotherapy and radiation therapy) for bladder or other pelvic malignant or benign disease. A quarter of the patients were aged > 75 years and 20% were octogenarians; 16% had been treated previously. Half had advanced pelvic disease (pT3-4) and 20% had positive lymph nodes. Surgical endpoints included soft-tissue margin status, extent of pelvic node dissection, number of nodes examined and individual surgeon volume.
Of the 16 surgeons, seven operated on < 50 cases, five on 50-100 and four completed > 100. There was no significant difference between surgeons or institutions in the surgical quality or type of patient operated, except the surgeons with the highest volume tended to operate on more elderly, sicker, and pre-treated patients than surgeons with lower volumes. Surgeons used a standard or extended bilateral node dissection in 80% of patients and 20% had a limited (9%) or no node dissection (11%). A limited node dissection was used in 35% of patients aged > 75 years and in half receiving previous extensive pelvic treatment. A standard node dissection was sometimes impractical if the operation had to be completed quickly in infirm patients, or was impossible because of previous pelvic surgery, chemotherapy or radiation. Table 1 shows the surgical outcomes of margin status, extent of node dissection and average node counts, accounting for patient variability. Although the overall positive margin rate was 6.5%, margins were positive in 12% of patients with locally advanced disease. Older, and pre-treated, patients had less extensive node dissections and lower node counts than younger, healthier patients who had not received previous pelvic therapy. The mean (median) number of nodes examined for all patients was 12.5 (11), but varied widely among individual patients having anatomically similar node dissections. This variability could be from anatomical differences between individuals or could reflect differences in the method of pathological review. Using such benchmarks, we think that experienced surgeons who regularly perform cystectomy (at least 10 per year) should achieve negative surgical margins in > 90% of cases and remove a mean of 10-14 nodes, recognizing that such standards will not be met in some of the most difficult cases.
STANDARDIZATION OF RADICAL CYSTECTOMY
Last, the issue of standards raises two questions. First, with so many variables to be counted, can acceptable and clinically useful standards for cystectomy be established at all? We think that general guidelines can be proposed, based on robust data combined from many institutions and surgeons performing cystectomy in largely unselected patients, rather than the experience of one surgeon. Surgeons are accountable for surgical margins, extent of node dissection and nodes because they are proxy measures of surgical quality correlating with bladder cancer outcome.
Second, are surgical standards important? We think they are for the outcome in individual patients, and for the design and evaluation of multimodal studies in bladder cancer. Who, where and how well surgery is performed could influence follow-up care, including adjuvant therapies. Recognized and accepted standards might also serve to elevate the overall quality of cystectomy in the future. This alone may prove to be as or more important than anticipated improvements in chemotherapy.
The practical issues involved in creating uniform standards for cystectomy can be formidable but are clearly surmountable. It is time for surgeons to count, and be counted. It is generally accepted that the presence of seminal vesicle invasion (SVI) in a resected specimen is an unfavourable prognostic factor in prostate cancer [1] [2] [3] . SVI has been reported in 5-13.6% of recent radical prostatectomy specimens [4] [5] [6] . Various studies have assessed the prediction of recurrence and prognosis in patients with prostate cancer and SVI treated by radical prostatectomy. In these studies, factors influencing prognosis have been identified by retrospective analysis, and include preoperative PSA level, age, Gleason score (biopsy and resected specimen) and percentage of cancer in biopsy specimens
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In refining these criteria, Ramsden and Chodak [12] described a significant improvement in prognosis for men with SVI if the histology showed negative margins, unilateral SVI or perineural invasion. They concluded that this may be applied to patients with SVI to direct adjuvant therapy and guide postoperative counselling.
At the other end of the prognostic spectrum, what should the surgical approach be with regard to the SVs? It has been suggested that predicting SVI before surgery would enable surgeons to develop a SV-sparing prostatectomy, in the belief that this may reduce morbidity. It has been argued that preserving the SVs may result in less dissection close to the neurovascular bundle, with a theoretically lower risk of damaging it. It still has to be determined whether extirpation of the SVs changes the outcome. Some argue that SVI is the harbinger of metastatic disease, and therefore that any radical local treatment is destined to fail if SVI is present.
There are several counter-arguments; after the prostate has been removed the SVs serve no known purpose, and that the higher risk to the neurovascular bundle might be from dissection around the prostatic apex, rather than during SV dissection. In addition, there is a risk of leaving undetected carcinoma from isolated metastasis to the SV tip, even if the cut margins of the amputated SV are free from tumour. Type 3 SVI (isolated metastasis) is found in 13% of specimens containing SVI [13].
The current approach by some British surgeons is partial amputation of the SVs, as opposed to complete excision. This permits some pathological assessment of SVI, allowing an evaluation of the prognosis. Traditionally, unlike lymph node sampling, it was thought that resecting the SVs was of therapeutic rather than diagnostic value. It is likely that tumour metastasis to the tip of the SV would be missed by this technique. However, it is unlikely that SV dissection would be therapeutic if SVI is present.
Unfortunately With more conservative treatment it was reported that the ipsilateral recurrence rate is high (a third) but there were few patients in the study (14) and the follow-up was 2-11 years [3] . To minimize the risk of recurrence and because of the success of intravesical agents in the treatment of superficial TCC of the bladder, several reports have investigated their role in adjuvant treatment after organsparing surgery of the upper tracts. BCG therapy has been most commonly used but other agents, including mitomycin C, thiotepa,
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adriamycin and interferon-a have also been tried. The agent can be instilled directly through a nephrostomy tube after the position has been checked by imaging, to prevent obstruction or extravasation. In ANH, 1-3 units of whole blood are drawn from the patient after the onset of anaesthesia and the volume is replaced with colloid or crystalloid volume expanders. Any blood lost during surgery is therefore more dilute and the withdrawn blood can be reinfused at the end of the procedure.
In modern cell salvage techniques (IOCS) salvaged blood is aspirated from the surgical field, anticoagulated in the suction device and then collected in a sterile collection container. When an adequate amount of blood has been collected it is pumped into a spinning centrifuge bowl. Red cells, being the heaviest components of blood, collect at the lowest point in the bowl and supernatant containing the other components of blood spill over into a waste bag. Sterile saline solution is pumped through the spinning centrifuge bowl and displaces the lighter remaining contaminants. Once this process is complete the red blood cells are re-suspended and can be transfused, usually immediately, or can be stored under specific conditions for up to 6 h.
IOCS has become the mainstay of many general surgical operations where there is a large volume blood loss, e.g. ruptured aortic aneurysm repair, greatly reducing the need for homologous blood transfusion. However, there has been concern that IOCS is not safe in the presence of malignant disease, because malignant cells may spill into the operative 
